475 results about "Target therapy" patented technology

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The invention discloses a skin targeted therapy laser control method and system based on a dual-wavelength synergistic effect, and the method comprises the steps: collecting the real-time morphological characteristics and pigment distribution data of skin tissues through a multispectral imaging unit, and recognizing the optical characteristic parameters of a target treatment region; generating a dual-wavelength combination scheme through a dynamic wavelength selection algorithm based on the optical characteristic parameters and the tissue structure characteristics of the target treatment area; according to a dual-wavelength combination scheme, generating a synergistic laser sequence with a specific pulse interval and energy ratio; the synergistic laser sequence is converted into a driving signal, and a dual-wavelength laser is controlled to output composite laser; and laser output parameters are dynamically adjusted through real-time thermal diffusion monitoring and an optical feedback mechanism. By utilizing the embodiment of the invention, accurate and selective heat dissipation of skin target tissues can be realized, surrounding normal tissues are effectively protected, the treatment safety and effectiveness are improved, and side effects are reduced.

The invention discloses a method for identifying the effectiveness of a Cas target spot by combining a gene large model and ML, and belongs to the field of biotechnology and artificial intelligence. The method comprises the following steps: constructing a detection array of A types of combined sequences and targeted combined sequences, wherein the detection array is provided with A detection units; respectively adding a combined sequence into each detection unit, carrying out incubation reaction, obtaining a fluorescence value of each detection unit, and carrying out normalization processing; carrying out key feature extraction on each combined sequence by adopting a feature extraction model; constructing a label set and a training set, constructing an integrated model, and training by adopting the label set and the training set; forming a machine learning model by the feature extraction model and the trained integrated model; and combining the new target sequence and the PAM sequence into a to-be-analyzed combined sequence, inputting the to-be-analyzed combined sequence into the machine learning model to obtain a predicted fluorescence value, and judging the recognition capability of the Cas protein on the combined sequence based on the fluorescence value. The method can assist in targeted therapy detection.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

The invention provides an antibody drug conjugate property prediction method based on multi-modal fusion, and belongs to the field of bioinformatics. The method comprises the following steps: firstly, explicitly modeling sequence position information through sine position coding; secondly, introducing a bidirectional cross attention mechanism to establish interaction between a light chain and a heavy chain and alignment between an antigen and an antibody; thirdly, the integrated graph neural network reconstructs the adjacency relation according to the attention weight, and topological features are extracted; and finally, in combination with a double-stage self-adaptive refining module, two-stage treatment of alignment and refining is realized, and each modal feature contribution is adjusted in a self-adaptive manner. And meanwhile, the sequence robustness is improved through Mask perception feature extraction, and the interpretability analysis of the key binding sites is realized through the attention weight. The method can significantly improve the prediction accuracy, and can be widely applied to cancer targeted therapy and drug design optimization.

The invention relates to the field of biological medicine, in particular to a prodrug structure with ROS signal response performance and a preparation method and application thereof. The prodrug molecule with ROS signal response performance developed by the invention can quickly release living active molecules in a disease signal ROS-enriched environment, and plays a role in targeted therapy. The method has good universality, prodrug modification can be carried out on multiple molecules, four kinds of drug molecules approved to appear on the market are included, and it is verified that the solubility and biocompatibility of drugs can be improved, cytotoxicity can be reduced, and the effect of targeted therapy can be improved. Based on the structural characteristics of the molecules, the molecules can also be complexed with PVA hydrogel, and responsive controllable release of the medicine is further achieved.

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention discloses an application of imatinib mesylate in preparation of a targeted therapeutic drug for gastric signet ring cell carcinoma. The imatinib mesylate has an obvious inhibition effect on the growth of six patients with the pathological type of gastric signet-ring cell carcinoma, the inhibition effect is more obvious along with the increase of the concentration, the concentration and dosage dependency relationship is shown, and the half inhibitory concentration (IC50) is obviously smaller than that of a positive control drug apatinib. The medicine can play a targeted therapeutic role on the gastric signet ring cell carcinoma, and is small in toxic and side effects, economical, practical and low in cost.

The invention discloses a viral ARDS prognosis evaluation system based on protein joint detection, and the system comprises a sample processing module which is used for carrying out serum standardization pretreatment; the protein detection module is used for performing iBAQ quantification of IL6ST / FOXO3 / TLR7 based on DIA mass spectrometry, defining a targeted therapy threshold value and realizing targeted quantification of the core protein; and the intelligent analysis module is used for realizing cross-age risk layering based on a multivariable logic regression model. B cell function states are reflected by combining serum IL6ST / FOXO3 / TLR7 protein expression levels, a multivariable logistic regression model is constructed, and unified risk stratification of patients of all ages from children to the elderly is achieved; by locking an IL6ST / FOXO3 / TLR7 pathway, a targeted therapy threshold is defined to directly guide targeted therapy, and immune intervention is facilitated.

The invention relates to a silicon-based nano material for targeted therapy of brucellosis as well as a preparation method and application of the silicon-based nano material. The invention relates to a preparation method of a silicon-based nano material for targeted therapy of brucellosis. The preparation method comprises the following steps: (1) preparing magnetic mesoporous silica; (2) aminating the magnetic mesoporous silica, and modifying the magnetic mesoporous silica with a responsive material and yeast beta-glucan to obtain modified magnetic mesoporous silica; and (3) carrying out antibiotic loading on the modified magnetic mesoporous silica. According to the silicon-based nano material for targeted therapy of brucellosis as well as the preparation method and the application of the silicon-based nano material, the surface of magnetic macroporous mesoporous silica is modified with yeast beta-glucan capable of targeting M cells and glutathione responsive molecules, and a drug delivery system sensitive to a brucellosis environment is synthesized; the nano-carrier has targeted targeting selectivity for delivering and releasing drugs, the activity, slow release and target cell uptake efficiency of antibiotics are ensured, and the brucellosis treatment is more accurate and efficient.

Described are devices and methods for administering targeted ultrasound therapy. The device consists of a wearable housing designed to conform to a part of the user's body, with an array of ultrasound transducer units on the skin-facing side. These transducers can generate ultrasound therapy to a target therapy area of the user, with frequency, intensity, treatment area, and duration parameters optimized for a therapeutic application. Incorporated within the device is a communication system, an energy source, and a processor. The processor's role is to execute instructions, including assessing the user's health status based on received data, processing and analyzing ultrasound data to gauge transmission quality, determining if the current transmission quality is within thresholds, initiating ultrasound therapy when the conditions are right, and adjusting ultrasound therapy parameters real-time or near real-time if needed during treatment. The real-time or near real-time adjustment is made through various parameters like pulsing frequency, pulse train frequency, the number of treated spots, duration, and treatment zone area. This device provides a personalized, adaptive approach to ultrasound therapy, optimizing the treatment process for each individual user.

The invention discloses a cell lineage tracking system based on synNotch and CRISPR / Cas9 bar code technology and application thereof, the cell lineage tracking system comprises a system mGFP ligand vector for constructing Sender ligand cells and a system for constructing Receiver recipient cells, and the system comprises a synNotch receptor-rtTA fusion vector, a TetO-Cas9 expression vector, a gRNA expression vector and a Target vector library containing a Barcode sequence. A synNotch system and a CRISPR / Cas9 gene editing technology are combined with a bar code strategy, a unique bar code is generated, the contact sequence between cells is recorded, the method is compatible with a single-cell sequencing technology, transcription information of the cells is provided, long-term tracking of the contact history between the cells is achieved, the method can be used for tracking interaction and functions between the cells in a tumor microenvironment, and the application prospect is wide. Through long-term tracking and functional analysis of interaction between macrophages, especially macrophages and tumor cells, the accuracy of interaction analysis is remarkably improved, and a more accurate target spot is provided for targeted therapy.

The invention relates to the technical field of biology, and provides a genetic marker for children nephrotic syndrome genetic risk assessment. The invention relates to genetic detection and application of hormone sensitive nephrotic syndrome (pSSNS) of children. Nine risk sites, including new sites of 1q23.1, 1p36.13, 5p13.2, 10q21.3, 10q24.1 and the like, highly related to diseases are found by integrating whole genome association research (GWAS) data, combining Meta analysis and a conjugate false discovery rate (conjFDR) method and taking genetic information of IgA nephropathy as assistance. Research results show that genes near the loci have differential expression in pSSNS and IgAN patients, which prompts that the genes play an important role in the occurrence and development of diseases. The invention provides a molecular detection method based on the risk site, which can be used for risk assessment, auxiliary diagnosis and prognosis prediction of children's nephropathy. Meanwhile, the invention provides potential application values of the loci and related genes thereof in individualized medication and targeted therapy.

The invention belongs to the technical field of biological medicines, and particularly discloses a pyrimidine derivative as well as a preparation method and application thereof. The structure of the pyrimidine derivative is as shown in formula I in the specification. The novel pyrimidine derivative capable of efficiently inhibiting the LSD1 activity is provided, the preparation process is simple and easy to implement, the good effect of resisting colorectal cancer cell proliferation is shown on the animal level, and safe and effective candidate drug molecules are provided for targeted therapy of colorectal cancer.

The invention discloses a solid lipid nanoparticle-inulin gel compound for targeted therapy of ulcerative colitis and a preparation method of the solid lipid nanoparticle-inulin gel compound, and belongs to the technical field of medicines, the compound comprises inulin gel and solid lipid nanoparticles dispersed in the inulin gel; the solid lipid nanoparticle comprises a glyceride shell, oleic acid coated by the glyceride shell, a medicine with anti-inflammatory and anti-oxidation effects, and cationic lipid, the mass ratio of the oleic acid to the medicine with the anti-inflammatory and anti-oxidation effects to the cationic lipid is 1: (1-1.5): (2.5-3); the drug loading capacity in the solid lipid nanoparticles is 1 to 10 weight percent. According to the compound, the inulin gel serves as a delivery system, functional solid lipid nanoparticles are carried in the compound, intestinal ferroptosis can be reduced, active oxygen can be removed, the compound has the effects of promoting intestinal barrier repair, relieving inflammatory response and the like, and the compound has good application prospects in the aspect of treatment of ulcerative colitis.

A cage-like nanocarrier for targeted delivery of siRNA, and a preparation method therefor and the use thereof. The preparation method comprises: (A) mutating a negatively charged or uncharged amino acid on the inner surface of a ferritin into a positively charged amino acid; and any one or more of the following steps: (B) coupling the N-terminus of the ferritin to a functional peptide having nucleic acid affinity; (C) coupling the N-terminus of the ferritin to a functional peptide promoting lysosomal escape; (D) truncating the E-helix at the C-terminus of the ferritin; (E) coupling the C-terminus of the ferritin to a functional peptide having nucleic acid affinity; and (F) coupling the C-terminus of the ferritin to a functional peptide promoting lysosomal escape. A new nucleic-acid-loaded protein nanocage carrier is constructed by means of modifying a negatively charged inner cavity of ferritin to make same positively charged. By means of electrostatic adsorption, a negatively charged siRNA can be efficiently loaded into a ferritin nanocage, thereby significantly improving the in-vivo and in-vitro delivery stability of siRNA, lysosomal escape functions, and efficacy of targeted therapy.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The invention discloses a design method and application of a tyrosinase (TYR) responsive drug for targeted therapy of melanoma, and belongs to the technical field of biological medicines. Based on the biological mechanism that TYR catalyzes tyrosine oxidation, a self-degradation connecting arm drug release strategy is combined, a similar 3-hydroxybenzyl alcohol structure is introduced to simulate a tyrosine substrate, specific recognition and activation of TYR on the drugs are achieved, and the problems that traditional chemotherapeutic drugs are poor in targeting property and serious in adverse reaction are hopefully solved.

An ultrasound therapy device for generating ultrasound therapy. The ultrasound therapy device includes a wearable structure, ultrasound transducer units, a tightening mechanism, a memory, and a processor. The wearable structure is securable to a user to transmit the ultrasound to a target therapy area of a user including at least one of a kidney region, a lung region, and a lower limb of the user. The ultrasound transducer units are attachable and repositionable in the wearable structure to generate and deliver the ultrasound to the target region. The ultrasound transducer units are arranged in an array. The array of ultrasound transducer units is mechanically moved within the wearable structure and is in contact with a material to facilitate penetration of ultrasound into the user's body.

The invention relates to a radionuclide labeled trimer probe 68Ga-TRAP-(FAPI) 3 targeting FAP and a preparation method thereof, Trap is used as a trivalent chelating platform, and three FAPI targeting units are covalently connected by clicking a chemical linking arm to form a trimer structure; the invention further relates to application of the 68Ga-TRAP-(FAPI) 3 probe in preparation of imaging agents or therapeutic drugs for diagnosing FAP positive diseases, experiments prove that the trimer probe is good in affinity and high in stability, and in cell experiments and animal experiments, the uptake rate of FAP positive cells is kept at a high level within 240 minutes; preclinical and preliminary clinical applications show that the tumor detection rate of the < 68 > Ga-TRAP-FAPI 3 in various cancer models is superior to that of < 18 > F-FDG, and compared with < 68 > Ga-FAPI-04, the < 68 > Ga-TRAP-FAPI 3 is clearer to display focuses (particularly tiny metastases), higher in uptake intensity and particularly outstanding in delayed imaging, and the < 68 > Ga-TRAP-FAPI 3 can be used for preparing a medicine for treating cancer. And a novel drug candidate with better performance is provided for precise diagnosis and staging of tumors and subsequent radionuclide targeted therapy.

Lung cancer is the leading cause of cancer deaths worldwide. Metastatic non-small-cell lung cancer (NSCLC) has recently benefited from two consecutive breakthroughs: the identification of oncogene drivers, such as KRAS mutations, leading to the development of targeted therapies, and the understanding of the cancer immunity cycle leading to the development of immune checkpoint inhibitors. KRASG12C mutations can be found in approximately 13% of patients with non-small-cell lung cancer (NSCLC) and historically have been associated with a poor prognosis. Now, data from a phase II trial demonstrate the efficacy of the novel KRASG12C-specific inhibitor sotorasib for patients with advanced-stage NSCLC harbouring this alteration with disease progression on at least one standard-of-care therapy. However one could expect that resistance to Ras inhibitors could occur and that there is a need for identifying new therapeutic avenues for limiting said resistance. The inventors now show that when use alone, sotorasib and tipifarnib did not show a significant anti-tumor effect on lung cancer cells harboring the G12C KRAS mutation, whereas the combination potently induced cell death, suggesting a synergism between these drugs. The present invention thus relates to the combination of Ras inhibitors and famesyltransferase inhibitors for the treatment of cancers.

The invention discloses a PET (positron emission tomography) imaging agent, a precursor and a probe for targeting an EphA2 receptor as well as a preparation method and application of the PET imaging agent, the precursor and the probe, and a radioactive probe which is formed by labeling a chelating agent (such as DOTA and NOTA) and a radionuclide (such as 68Ga) by taking bicyclic peptide as a targeting group is specifically combined with the EphA2 receptor highly expressed on the surface of a tumor cell. According to the invention, a conformation limitation strategy is adopted for transforming the peptide probe targeting EphA2 for the first time, the bicyclic peptide radioactive probe with excellent targeting performance and in-vivo imaging effect is obtained, the tumor uptake value is high, and tumor and non-tumor imaging is clear; and successful imaging in a fibrosarcoma model. According to the EphA2 receptor-targeted PET imaging agent provided by the invention, the precursor, namely the probe, has the advantages of simplicity in preparation, good targeting property, excellent imaging effect and the like, can be used for PET imaging diagnosis, prognosis evaluation and targeted therapy guidance of EphA2 positive tumors, and has good clinical value.

The invention discloses a magnetic-aptamer targeting tumor tissue nano-drug delivery system as well as a preparation method and application thereof, and belongs to the field of medicines. The system comprises a mesoporous ferroferric oxide magnetic core, a polyethyleneimine (PEI) layer coated outside the mesoporous ferroferric oxide magnetic core and an aptamer adsorbed outside the PEI layer, and an autophagy activator can be selectively loaded in the mesoporous core. The preparation method comprises the following steps: sequentially carrying out drug loading, PEI coating and aptamer modification on the mesoporous Fe3O4 nanoparticles. According to the invention, efficient enrichment and endocytosis of tumor tissues are realized through dual effects of magnetic targeting and active targeting of the aptamer; lysosome escape is promoted by using the proton sponge effect of PEI; finally, by virtue of the synergistic effect of iron ions released by degradation of the Fe3O4 nanoparticles and endogenous iron ions released by ferritin autophagy induced by an autophagy activator, ferroptosis of tumor cells is induced through enhanced Fenton-like reaction, so that high-efficiency and low-toxicity targeted therapy is realized.

The invention relates to the technical field of biochemistry, and particularly discloses a galactosyl zinc-porphyrin derivative and a preparation method and application thereof.The galactosyl zinc-porphyrin derivative is formed by coupling a group with double functions of fluorescence and cytotoxic activity and a liver cancer targeting group, can be specifically combined with a liver cancer cell HepG2, emits 608 nm and 659 nm fluorescence signals under the excitation wavelength of 425 nm, and can be used for detecting liver cancer. And accurate tracing can be realized. Meanwhile, IC509.1 mu M + / -2.59 is used for killing liver cancer cells, so that targeted therapy is realized. The chemical disclosed by the invention has the functions of fluorescence tracing and targeted killing, can synchronously realize accurate positioning (fluorescence tracing) and efficient removal (targeted treatment) of liver cancer cells without drug combination, can be used for liver cancer diagnosis, treatment and curative effect evaluation, and has extremely high research and development value.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention provides an anti-CD16a single-domain antibody and an application of the anti-CD16a single-domain antibody. In particular, the invention provides a specific single domain antibody for resisting human CD16a. The invention also provides a coding sequence for coding the single-domain antibody or the VHH chain thereof, a corresponding expression vector, a host cell and a method for producing the single-domain antibody. The single-domain antibody provided by the invention has high affinity and high specificity, and can be used for detection and targeted therapy of CD16a.

The present invention provides the use of an agent targeting the interaction between STC2 and Cav1.2 in the preparation of a drug for tumor prevention, treatment, or drug resistance enhancement. The agent targeting the interaction between STC2 and Cav1.2 is selected from an agent that inhibits STC2 expression, an agent that promotes Cav1.2 expression, or a combination of the two. The interaction between STC2 and Cav1.2 discovered in the present invention can be used for targeted therapy of ovarian cancer or other tumor types.

The invention provides an application of a human C1orf186 gene or a human C1orf186 protein in preparation of a targeted therapeutic drug for ovarian cancer, and relates to the technical field of biomedical engineering. The invention relates to an application of a human C1orf186 gene or a human C1orf186 protein in preparation of an ovarian cancer targeted therapy drug. Experiments prove that C1orf186 is an ovarian cancer cell surface specific membrane protein molecule, a C1orf186 positive cell population has tumor stem cell characteristics, and prepared human C1orf186 lentivirus packaging plasmids and other targeted therapeutic drugs have an obvious inhibition effect on the growth of ovarian cancer. Therefore, the invention provides a specific target C1orf186 for molecular therapy of the ovarian cancer, also provides several targeted drug types, and more importantly provides a thought for treating the ovarian cancer by using the anti-C1orf186 targeted drug, thereby laying a foundation for deeply researching the function of the C1orf186. Meanwhile, the invention provides reliable theoretical basis and experimental data for clinical treatment of ovarian cancer, and has important significance and wide prospects.

This invention discloses a lipid assembly loaded with 5-aminolevulinic acid and its preparation method. The lipid assembly is a hollow sphere with a core consisting of a hydrophilic phospholipid-chelating agent conjugate formed by chelation with a reactive phospholipid PEG reagent. The outer layer of the phospholipid-chelating agent conjugate is loaded with 5-aminolevulinic acid via hydrazone bonds, and then combined with a radionuclide as an internal light source excitation photosensitizer. The lipid assembly is loaded with 5-ALA via hydrazone bonds. Utilizing the acid-sensitive bond-breaking characteristics of hydrazone bonds and the prodrug properties of 5-ALA, combined with a radionuclide labeled on the surface of the lipid assembly as an internal light source excitation photosensitizer, this invention can overcome the limitations of external light penetration depth in traditional photodynamic therapy, achieving deep PDT treatment. Combined with chemotherapy drugs, it can minimize the toxic side effects on normal tissues during the combined use of radionuclides and photosensitizers in targeted therapy.